Skip to main content

← All trials/NCT07732738

BS-GLP

RecruitingPhase NA

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Obesity: A Prospective, Multicenter Cohort Study

Lead sponsor

China-Japan Friendship Hospital

Asset

Semaglutide

GLP-1 agonist

Listed sites

7

Recruiting sites

7

Estimated enrollment

400

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥27.5

Primary endpoint

•Percentage of weight loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07732738

Org study IDBS-GLP-Multic-CN

Timeline

Milestones

Study start2025-01-01actual

Study first posted2026-07-29actual

Last update posted2026-07-29actual

Primary completion2027-12-30estimated

Study completion2027-12-30estimated

Assets

Investigational agents

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age16 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).

2. obesity:BMI ≥27.5 kg/m².

3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.

4. Age range: 16-70 years (inclusive).

5. Informed consent: Willing participation with documented consent.

Exclusion criteria

1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.

2. Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.

3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).

4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.

5. Significant comorbidities:

Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR <30 mL/min/1.73m²) Active malignancy (except non-melanoma skin cancers) Autoimmune disorders requiring immunosuppression Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)

Endpoints (22)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

6

Other (unclassified)

5

Weight & body composition

4

Glycemic / diabetes

3

MASH / liver

2

Renal / kidney

2

Weight & body composition

4 endpoints

Primary/protocol endpoint

the Percentage of weight loss

Time frame:1 year

descriptive

Secondary/protocol endpoint

Weight in kilograms

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Waist circumference in centimeters

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other/protocol endpoint

Visceral fat area

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Glycemic / diabetes

3 endpoints

Secondary/protocol endpoint

Fasting blood glucose

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Postprandial 2-hour blood glucose

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

HbA1c

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

MASH / liver

2 endpoints

Secondary/protocol endpoint

Alanine Aminotransferase(ALT)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Aspartate Aminotransferase(AST)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Renal / kidney

2 endpoints

Secondary/protocol endpoint

Serum creatinine

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Glomerular filtration rate

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

ratio, improvement

Cardiometabolic biomarkers

6 endpoints

Secondary/protocol endpoint

Total cholesterol

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Low-Density Lipoprotein(LDL)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

High-Density Lipoprotein(HDL)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Triglycerides

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

uric acid(UA)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Blood pressure

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other (unclassified)

5 endpoints

Other/protocol endpoint/low confidence

body fat percentage(BFP)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other/protocol endpoint/low confidence

Muscle mass in kilograms

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other/protocol endpoint/low confidence

Body fat percentage

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other/protocol endpoint/low confidence

lean body mass (LBM)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other/protocol endpoint/low confidence

lean body mass percentage (LBMP)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.